...
首页> 外文期刊>The breast journal >Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival
【24h】

Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival

机译:一系列侵袭性导管癌和侵袭性小叶癌患者的长期比较研究。局部区域复发,转移和生存

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Our aim was to compare histologic and immunohistochemical features, surgical treatment and clinical course, including disease recurrence, distant metastases, and mortality between patients with invasive ductal carcinoma (IDC) or invasive lobular carcinoma (ILC). We included 1,745 patients operated for 1,789 breast tumors, with 1,639 IDC (1,600 patients) and 145 patients with ILC and 150 breast tumors. The median follow-up was 76months. ILC was significantly more likely to be associated with a favorable phenotype. Prevalence of contralateral breast cancer was slightly higher for ILC patients than for IDC patients (4.0% versus 3.2%; p=n.s). ILC was more likely multifocal, estrogen receptor positive, Human Epidermal Growth Factor Receptor-2 (HER2) negative, and with lower proliferative index compared to IDC. Considering conservative surgery, ILC patients required more frequently re-excision and/or mastectomy. Prevalence of stage IIB and III stages were significantly more frequent in ILC patients than in IDC patients (37.4% versus 25.3%, p=0.006). Positive nodes were significantly more frequent in the ILC patients (44.6% versus 37.0%, p=0.04). After adjustment for tumor size and nodal status, frequencies of recurrence/metastasis, disease-free and specific survival were similar among patients with IDC and patients with ILC. In conclusion, women with ILC do not have worse clinical outcomes than their counterparts with IDC. Management decisions should be based on individual patient and tumor biologic characteristics rather than on lobular versus ductal histology.
机译:我们的目的是比较浸润性导管癌(IDC)或浸润性小叶癌(ILC)患者之间的组织学和免疫组化特征,手术治疗和临床过程,包括疾病复发,远处转移和死亡率。我们纳入了1,745例因1789例乳腺肿瘤而手术的患者,1639例IDC(1600例患者)和145例ILC和150例乳腺肿瘤的患者。中位随访时间为76个月。 ILC明显更可能与有利的表型有关。 ILC患者的对侧乳腺癌患病率略高于IDC患者(4.0%对3.2%; p = n.s)。与IDC相比,ILC更可能是多灶性,雌激素受体阳性,人表皮生长因子受体2(HER2)阴性,且增殖指数较低。考虑到保守手术,ILC患者需要更频繁的再次切除和/或乳房切除术。 ILC患者的IIB和III期患病率明显高于IDC患者(37.4%对25.3%,p = 0.006)。 ILC患者中阳性淋巴结的发生率明显更高(44.6%对37.0%,p = 0.04)。调整肿瘤大小和淋巴结状态后,IDC患者和ILC患者的复发/转移频率,无病生存率和特定生存率相似。总之,患有ILC的女性的临床结局没有比患有IDC的女性更差。管理决策应基于患者和肿瘤的生物学特性,而不是小叶与导管的组织学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号